Earnings Call Summary | Vanda Pharmaceuticals(VNDA.US) Q1 2024 Earnings Conference
Earnings Call Summary | Vanda Pharmaceuticals(VNDA.US) Q1 2024 Earnings Conference
The following is a summary of the Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript:
以下是万达制药公司（VNDA）2024年第一季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Vanda Pharmaceuticals posted total revenues of $47.5 million for Q1 2024, representing a 24% decrease from the $62.5 million reported for Q1 2023.
The company recorded a net loss of $4.1 million, compared to a net income of $3.3 million in the first quarter of 2023.
Vanda's product, PONVORY accounted for net product sales of $6.8 million in the first quarter of 2024.
As of March 31, 2024, Vanda had $394.1 million in cash, cash equivalents, and marketable securities.
万达制药公布的2024年第一季度总收入为4,750万美元，较2023年第一季度报告的6,250万美元下降了24％。
该公司净亏损410万美元，而2023年第一季度的净收入为330万美元。
万达的产品PONVORY在2024年第一季度的产品净销售额为680万美元。
截至2024年3月31日，万达拥有3.941亿美元的现金、现金等价物和有价证券。
Business Progress:
业务进展：
Vanda's drug, Fanapt was approved as a first-line therapy for the acute treatment of manic or mixed episodes associated with Bipolar I disorder in adults, with an NDA for psychiatric disorders expected to be submitted by early 2025.
The company initiated clinical programs for Fanapt and Milsaperidone in the treatment of depressive symptoms, with a plan to have Fanapt LAI (long-acting injectable) formulation on the U.S. market post-2026.
Vanda acquired PONVORY, a once-a-day oral treatment for people with multiple sclerosis in December 2023, with a focus on preparing for U.S. commercial launch and evaluating its potential application for psoriasis and ulcerative colitis.
Tradipitant, another product by Vanda is under FDA review for the treatment of gastroparesis with an action date set in September 2024, and a filing expected for motion sickness by the end of the year.
The company plans to increase awareness of PONVORY as a potential treatment for multiple sclerosis and exploit its application in autoimmune disorders.
Despite the current business conditions, Vanda remains open to evaluating any and all potential acquisitions, and remains committed to its mission as a standalone company with three commercial assets and a robust late-stage pipeline.
Vanda的药物Fanapt被批准为急性治疗成人躁狂或混合发作的一线疗法，用于急性治疗与I型双相情感障碍相关的混合发作，针对精神疾病的保密协议预计将于2025年初提交。
该公司启动了用于治疗抑郁症状的Fanapt和Milsaperidone的临床项目，并计划在2026年后将Fanapt LAI（长效注射剂）配方在美国市场上市。
Vanda于2023年12月收购了PONVORY，这是一种针对多发性硬化症患者的每天一次的口服疗法，重点是为美国的商业上市做准备，并评估其在牛皮癣和溃疡性结肠炎方面的潜在应用。
Vanda的另一款用于治疗胃轻瘫的产品Tradipitant正在接受美国食品药品管理局的审查，其生效日期定为2024年9月，预计将在年底前提交晕车申请。
该公司计划提高人们对PONVORY作为多发性硬化症潜在治疗方法的认识，并利用其在自身免疫性疾病中的应用。
尽管目前的业务状况不佳，但Vanda仍然愿意评估所有潜在的收购，并将继续致力于实现其作为一家拥有三项商业资产和稳健后期投资渠道的独立公司的使命。
More details: Vanda Pharmaceuticals IR
更多详情： 万达制药投资者关系
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。